Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy

Mayako Uchida, Hiroaki Ikesue, Koji Kato, Kimiko Ichinose, Hiromi Hiraiwa, Asako Sakurai, Katsuto Takenaka, Hiromi Iwasaki, Toshihiro Miyamoto, Takanori Teshima, Nobuaki Egashira, Koichi Akashi, Ryozo Oishi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. Methods. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). Results. A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m2/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. Conclusion. The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalAmerican Journal of Health-System Pharmacy
Volume70
Issue number4
DOIs
Publication statusPublished - Feb 15 2013

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Health Policy

Cite this